O. Horvath

From obesity and sedentary lifestyle to energetic and metabolic failure: empagliflozin and semaglutide reverse mitochondrial and metabolic dysfunction in experimental HFpEF

HFpEF accounts for nearly half of all heart failure cases and carries substantial morbidity and mortality. Beyond hemodynamic abnormalities, it is now increasingly recognized as a systemic metabolic disorder driven by obesity, insulin resistance, and chronic low-grade inflammation. Mitochondrial dysfunction plays...